Neurotech International executive director Dr Tom Duthy speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022. Neurotech is focused on the development and commercialisation of neurological solutions that improve quality of life. NTI’s current focus is a world-first clinical study utilising NTI164 in the treatment for paediatric Autism Spectrum Disorder (ASD).
#ProactiveInvestors #NeurotechInternational #ASX #autismspectrumdisorder #neurologicalsolutions
source
